EULAC PerMed - D2.3 “Workshop Report” 1
Disclaimer: Due to the situation of Covid-19 pandemic, this deliverable is pending formal
validation of European Commission
EULAC-PerMed has been funded by the European Union’s
Horizon 2020 Research and Innovation Programme under
Grant Agreement (GA) No 825173
Deliverable 2.3
STAKEHOLDERS WORKSHOP REPORT
EULAC PerMed - D2.3 “Workshop Report” 2
Project Acronym EULAC-PerMed
Project Title Widening EU-LAC policy and research cooperation in Personalised Medicine.
Grant Agreement no. 825173
Start date of the project
01/01/2019
End date of the project
31/12/2021
Work Package number
WP2 – MAPPING OF PERSONALISED MEDICINE INITIATIVES IN LAC REGION AND IDENTIFICATION OF GAPS AND NEEDS FOR BETTER FOSTERING INTEGRATION OF LAC COUNTRIES IN ICPerMed
Deliverable Number 2.3
Deliverable title “WORKSHOP REPORT”
Lead Beneficiary ANII
Due date M12 (Dec 2019)
Date of delivery M13 (Jan 2020)
Nature R (Report)
Dissemination level PU (Public)1
DISCLAIMER This document contains information which is the proprietary to the EU-LAC Consortium. Neither this document nor the information contained herein shall be used, duplicated or communicated by any means to any third party, in whole or in parts, except with prior written consent of the EU-LAC Coordinator. The information in this document is provided "as is", and no guarantee or warranty is given that the information is fit for any particular purpose. The document reflects only the authors’ view. The EU-LAC is not responsible for any use that may be made of the information it contains. The user uses the information at its solo risk and liability
Version Contributors Comments
1.0 ANII 1st draft
1.1 ANII and INNOVATEC 1st draft reviewed
1.2 ANII, INNOVATEC and CSO-MOH 1st draft reviewed
1.3 ANII, INNOVATEC, CSP-MOH, ISCIII Final version
1 The annexes no. II, III and IV of the report will not be included in the public edition for DP issues.
EULAC PerMed - D2.3 “Workshop Report” 3
Deliverable 2.3
“WORKSHOP REPORT”
Contents
Page
1. INTRODUCTION AND OBJECTIVES OF THE WORKSHOP 4
2. CONTENT OF THE WORKSHOP 4
2.1 WELCOME AND OPENING 5
2.2 KEYNOTE AND INVITED PRESENTATIONS 5
2.3 THEMATIC BLOCKS AND WORKING GROUPS 6
2.3.1 The situation of Personalised Medicine in Latin America and the Caribbean
6
2.3.2 Challenges and future perspectives of PM in Latin America and the Caribbean
7
2.3.3 Strengthening the EU-LAC collaboration in Personalised Medicine
8
3. PARTICIPANTS AND SPEAKERS 8
4. CONCLUDING REMARKS 11
ANNEX I - Agenda of the workshop 16
ANNEX II - List of participants 24
ANNEX III - Working groups 32
ANNEX IV - Gallery 37
EULAC PerMed - D2.3 “Workshop Report” 4
1. INTRODUCTION AND OBJECTIVES OF THE WORKSHOP
As part of the EULAC-PerMed project, a workshop intended for promoting the development
and broadening of EU-LAC policy and research cooperation in Personalised Medicine (PM),
took place during the 11th and 12th of December, in the city of Montevideo (Uruguay).
This workshop was constructed to serve as an initial step for building links with countries that
are interested in collaborating in PM and joining the ICPerMed initiative. With that purpose in
mind, we sought to gather LAC and EU actors from different stakeholder groups: Health
Policymakers & Funding Agencies, R&I Policymakers & Funding Agencies,
regional/international organizations active in health research and policy, universities and
research organizations, hospitals, scientific associations and networks, researchers, Public-
Private partnerships, Industry and Patient Associations and other civil organizations.
The workshop brought together EULAC-PerMed partners, representatives of ICPerMed,
European and LAC experts and the aforementioned stakeholders in order to share knowledge,
discuss options and provide recommendations towards building bridges in PM between Latin
America, the Caribbean and Europe.
The main objectives of the workshop were the following:
To present the work of the EULAC-PerMed project, concentrating on the results of the
mapping of PM in LAC.
To analyse and discuss with relevant actors from LAC the situation of PM in Latin
America and the Caribbean, while analyzing the main gaps and barriers, opportunities
and challenges ahead.
To discuss the best options to promote the collaboration between LAC and EU in PM
and how to best approach the science and policy dialogue to be carried out within the
EULAC-PerMed project.
The Workshop was carried out in the facilities of the LATU Technological Park (Avenida Italia
6201, Montevideo, Uruguay) and the organization was under the responsibility of INNOVATEC
and the National Research and Innovation Agency of Uruguay (ANII)
It is worth mentioning that the contents and speakers for the workshop were proposed by
INNOVATEC while the logistics aspects were arranged by ANII.
2. CONTENT OF THE WORKSHOP
In order to provide a general view of the content and activities that were offered during the
workshop, we present in this section of the report highlights from every session.
As it was mentioned before, the workshop was carried out during December 11th and 12th,
having a total duration of one and a half days (see Annex I – Workshop agenda).
EULAC PerMed - D2.3 “Workshop Report” 5
In order to better achieve the above mentioned objectives, the Workshop was structured as
follows:
Welcome and opening session
Two keynote presentations
Five invited presentations
Three thematic blocks, of which two included work in groups:
o The situation of PM in Latin America and the Caribbean
o Challenges and future perspectives of PM in Latin America and the Caribbean
o Strengthening the EU-LAC collaboration in PM.
2.1 WELCOME AND OPENING
The opening of the workshop took place on December 11th, in the presence of the Minister of
Health of Uruguay, Dr. Jorge Basso, the President of the National Research and Innovation
Agency of Uruguay (ANII), Eng. Fernando Brum and the Coordinator of EULAC PerMed Project,
Dr. Esther Rodríguez. They offered welcome words to the participants and the representatives
of Uruguay made a short speech on the importance of PM for the Health system as well as for
the development of research and innovation.
Following the opening session, there was a brief introduction to the objectives of the
workshop and to the participants. This was conducted by Joaquin Guinea from INNOVATEC.
The brief introduction was followed by a presentation of the EULAC PerMed Project by Esther
Rodríguez from ISCIII.
2.2 KEYNOTE AND INVITED PRESENTATIONS
The two keynote presentations, which took place on the first day of the Workshop, aimed at
making an introduction to the situation of PM in Europe and Latin America. The presentations
were the following:
KEYNOTE PRESENTATION 1: “THE GENOMIC INITIATIVE OF THE SPANISH SENATE AND ITS
ROLE IN PROMOTING THE NATIONAL STRATEGY OF PRECISION MEDICINE IN SPAIN”
Dr. José Martínez Olmos. Escuela Andaluza de Salud Pública. Ex - Senador y ex Portavoz de
la Comisión de Sanidad y Servicios Sociales.
KEYNOTE PRESENTATION 2: “A (personal) VISION OF PERSONALISED MEDICINE FROM
LATIN AMERICA AND CARIBBEAN”
Dr. Manoel Barral-Netto. FIOCRUZ (Brazil)
EULAC PerMed - D2.3 “Workshop Report” 6
The invited presentations took place on the second day of the workshop and were intended to
introduce some specific experiences in the development and support of PM in the EU and in
LAC countries.
The presentations were the following:
“THE ICPerMed INTERNATIONAL CONSORTIUM FOR PERSONALISED MEDICINE“
Dra. Ulrike Busshoff, ICPerMed Secretariat, DLR (Germany).
“CNPq ACTIVITIES IN PERSONALISED MEDICINE”
Professor João Azevedo, President of CNPq, National Council for Scientific and
Technological Development (Brazil)
“CELAC AND EUROPEAN CONSORTIUM FOR A PERSONALISED MEDICINE APPROACH TO
GASTRIC CANCER (LEGACy)”
Dra. Tania Fleitas Kanonnikoff- INCLIVA (Spain). Project Coordinator.
“PERSPECTIVES AND CHALLENGES FOR HUMAN BIOLOGICAL MATERIAL BIOBANKS IN THE
ADVANCE OF PERSONALISED MEDICINE: EXPERIENCE FROM THE LATIN AMERICA AND THE
CARIBBEAN BIOBANKS NETWORK (REBLAC)”
Dr. Gustavo Stefanoff. Coordinator of the Latin America and the Caribbean Network of
Biobanks (REBLAC). National Institute of Cancer José Alencar Gomes da Silva (INCA),
(Brazil)
“ERA-PerMed, ERA-NET ON PERSONALISED MEDICINE”
Dra. Esther Rodriguez, ISCIII (España)
2.3 THEMATIC BLOCKS AND WORKING GROUPS
In order to make an in-depth analysis of the situation in both EU and LAC countries regarding
the development of PM, which can provide valuable outputs for the objectives of the project,
the following three thematic blocks were established:
The situation of PM in Latin America and the Caribbean
Challenges and future perspectives of PM in Latin America and the Caribbean
Strengthening the EU-LAC collaboration in PM
2.3.1 Situation of PM in Latin America and the Caribbean
This thematic block started with the presentation of the results of the study “Mapping of
personalised medicine in LAC countries”, which is part of the project and was conducted by -
INNOVATEC (Spain) and Instituto GORGAS (Panamá).
After the presentation of the study, a roundtable discussion took place, where some relevant
experiences in PM from eight LAC countries were presented.
EULAC PerMed - D2.3 “Workshop Report” 7
The roundtable was composed as follows:
MEXICO: "The research in the National Institutes of Health towards Personalised
Medicine”
Dr. Rodolfo Cano Jiménez. Director of Health Research. Secretary of Health
BRAZIL: “The brazilian initiative in Precision Medicine BIPMed”.
Dr. Iscia Lopes-Cendes. Universidade Estadual de Campinas (UNICAMP). Faculdade de
Ciências Médicas (FCM).
CUBA: “The National Program in Precision Medicine”.
Dra. María Victoria Norabuena Canal, Chief of the Department of Research of the Direction
of Science, Technology and Innovation. Ministry of Public Health
CHILE: "Implementation of precision oncology: from research to clinical practice”
Dr. Ricardo Armisén, Chief Scientist. Center of Excellence in Precision Medicine (CEMP).
PERÚ: “Experience in studies of Precision Medicine: University of San Martin de Porres”
Dr. Liliana Vásquez, Principal Investigator, Center of Precision Medicine of the Faculty of
Medicine – University of San Martin de Porres.
COLOMBIA: “Closing gaps in Precision Medicine in Colombia: GenomaCES Biotechnologies”
Dr. Juan Esteban Gallo, Founder and Chief Scientist.
ARGENTINA: “Argentinian Initiatives in Precision Medicine”
Licc. Azul Irazoqui and Licc. Agustina Vello. Secretary of Science, Technology and
Productive Innovation of the Nation, Government of Argentina.
URUGUAY: “Opportunities for the development of predictive medicine in oncology.
Research and clinical practice”
Dr. Mauricio Cuello. Associated Professor of the Service of Oncology of the Manuel
Quintela Hospital. Vice-Director of the National Cancer Institute of Uruguay.
2.3.2 Challenges and future perspectives of PM in Latin America and the Caribbean
This block started with the presentation of two studies related to the theme to be addressed,
which were intended to serve as a kick-start for the later work done in groups. The results of
the following studies were presented:
“HEALTH INNOVATION POLICIES IN LATIN AMERICA AND ITS ROLE AS DRIVERS OF
PERSONALISED MEDICINE. PRESENTATION FROM THE RIMAIS STUDY”
Dr. Tomás López-Peña. ISCIII (España)/RIMAIS
“RESULTS OF THE SURVEY CHALLENGES AND PERSPECTIVES OF PERSONALISED
MEDICINE IN LATIN AMERICA AND THE CARIBBEAN”
Dr. Juan Miguel Pascale and Dr. Franz F. Castro, Instituto GORGAS (Panamá).
EULAC PerMed - D2.3 “Workshop Report” 8
After these two presentations, the audience was divided into four working groups and each
one of them had an assigned moderator and a rapporteur (representatives of partner
institutions of the EULAC PerMed project). The people assigned to each working group were
determined previously, in order to ensure balance in terms of representation of the different
stakeholders groups and also a balanced geographical distribution. The groups were of around
18-20 persons each.
Once the discussion phase was finished, a plenary session, in which every group presented
their results and a summary of the main findings that emerged, took place.
2.3.3 Strengthening the EU-LAC collaboration in personalised medicine
This thematic block started with a presentation entitled “SCIENCE & POLICY DIALOGUE
BETWEEN LAC COUNTRIES AND ICPERMED. NEXT STEPS”, which was carried out by Laura De La
Cruz from DLR (Germany)
After the presentation, the same four working groups that were assigned for 2.3.2 (including
their respective Moderator and Rapporteur) started a discussion on how to strengthen the
collaboration between EU and LAC countries in order to foster the development of PM in both
regions. Once the discussion was finished, each group shared their conclusions.
3. PARTICIPANTS AND SPEAKERS
At the closing date of the application submission to participate in the workshop, 87
applications were received. All of the applicants were admitted. Finally, a total of 73
participants effectively attended the activities (see Annex II).
Below is shown a table which indicates the composition of the audience and the speakers that
participated in the Workshop taking into consideration the region where they come from and
the stakeholder group to which they belong.
PARTICIPANTS
Stakeholder group N° of participants
EU LAC Others*
Health Policy Makers 2 14 -
Funding Agencies - 1 -
R&I Policy Makers & Funding Agencies - 9 -
Regional/international organizations active in health research and policy
- - 2
Universities and research organizations 10 22 -
Hospitals 1 3 -
Scientific associations and networks - 3 -
Public-Private partnerships - - -
Business/ Industry 2 4 -
Patient Associations - - -
Other Civil organizations - - -
TOTAL 15 56 2
EULAC PerMed - D2.3 “Workshop Report” 9
*There were also participants from USA
Chart 1. Participants by geographical region
Chart 2. Participants by stakeholders group
Health Policy Makers
Funding Agencies
R&I Policy Makers &Funding Agencies
Universities and researchorganizations
Hospitals
Scientific associations andnetworks
Business/ Industry
EULAC PerMed - D2.3 “Workshop Report” 10
SPEAKERS
Stakeholder group N° of speakers
EU LAC
Health Policy Makers 1 2
Funding Agencies - 1
R&I Policy Makers & Funding Agencies - -
Regional/international organizations active in health research and policy
1 -
Universities and research organizations 3 4
Hospitals - -
Scientific associations and networks - 1
Public-Private partnerships - -
Business/ Industry - 1
Patient Associations - -
Other Civil organizations - -
TOTAL 5 9
Chart 3. Speakers by geographical region.
EU
LAC
EULAC PerMed - D2.3 “Workshop Report” 11
Chart 4. Speakers by stakeholders group
4. CONCLUDING REMARKS
The workshop was successful in terms of achieving a significant participation of
representatives of the different stakeholders groups considered from both EU and LAC regions.
Moreover, very valuable contributions were collected from the participants and the speakers,
which constitute inputs for the analysis of the three aspects treated during the activity: actual
situation, challenges and future perspectives, and how to strengthen the collaboration
between EU and LAC countries for the development of PM. All those contributions were
properly recorded and are part of the Deliverable 2.22, where they are presented in detail.
Here we present a summary of the main conclusions regarding each of the issues that were
analyzed:
Challenges and future perspectives of PM in Latin America and the Caribbean
As presented in Deliverable 2.2, several main challenges were pointed out by the groups. They
can be addressed to the following categories:
1) Scientific and technological
2) Operational
3) Economic
4) Governance
2 EULAC-PerMed project. Deliverable D2.2: ANALYSIS OF STRENGTHS, WEAKNESSES, BARRIERS
AND GAPS FOR ICPerMed-LAC COOPERATION. Available at http://www.eulac-permed.eu/
Health Policy Makers
Funding Agencies
Regional/internationalorganizations active inhealth research and policyUniversities and researchorganizations
Scientific associations andnetworks
EULAC PerMed - D2.3 “Workshop Report” 12
1) Scientific and technological challenges
To assume and understand the existing diversity in the LAC region
Challenge more on the implementation side, and not in the scientific and technological
capacity of the region.
Being able to engage professionals from different disciplines to work together and
participate in PM clinical trials
To have a more in-depth knowledge of the genetic diversity of the different LAC
populations, together with epidemiological data of the countries. There are not many
genomic databases available in LAC, and without this, it is very difficult to advance in
the development of PM.
Establish mechanisms and regulations that facilitate the use of PM data for
researchers participating in international R&D projects.
Facilitate data interoperability.
2) Operational challenges (integrating PM into healthcare and clinical practice)
Guaranteeing access to PM drugs when investing in population genetic analyses and
PM clinical trials
Training and capacity building on genomic analysis for health care professionals
Better inform health policy and decision makers on the importance of PM
implementation in terms of cost reduction for the health systems.
Countries have to develop realistic PM strategies, taking into account the country
context and the type of diseases.
Adapt already existing PM standards
3) Economic
Lack of information about the most cost-effective technologies and infrastructure for
PM. Europe could support LAC countries in knowing and deciding what are the best
options when investing in expensive equipment.
Poor planning when acquiring innovative technologies (i.e. expensive and costly
equipment are bought and there are no qualified personnel available to use them)
EULAC PerMed - D2.3 “Workshop Report” 13
4) Governance
Establish long term healthcare policies that are not affected by political changes in the
country, and that take into account the need to invest in health research.
Include PM in the health policy agenda.
The healthcare systems always suffer expense cuts at times of economic deceleration
periods.
It is worth mentioning that besides this, a SWOT analysis was performed for each group. The
results are presented in Deliverable 2.2.
Strengthening the EU-LAC collaboration in PM
The main conclusions on this regard, as presented in Deliverable 2.2, are the ones summarized
below:
EU-LAC collaboration needs to be strengthened. It was also noted that there is a need
to strengthen the collaboration between LAC countries.
Collaboration with Europe should be horizontal, not top-down approaches, based on
equal partnerships and mutual benefits between the two regions.
Before collaborating with Europe, there is a need to have a common understanding in
the region of what PM is, knowing what resources are available in the region, and
making sure that decision makers have an understanding of PM. For this, it is
important to rely on already existing networks such as RIMAIS, COMISCA or seek the
collaboration of international organizations such as OPS/PAHO, to start introducing the
discussion of PM in the health policy agendas of the region.
Collaboration at both the scientific and political levels was found important and should
run in parallel. Since the research/academic sector is already “convinced” about PM,
the focus should be slightly shifted towards the political/policy level. It is important to
raise awareness among them about the potential benefits of PM. In this regard,
disseminating the benefits of PM in an understandable language for policy makers and
the general public is necessary.
Implementation of PM in the region should follow a stepwise approach, and each
country will advance based on its own circumstances and the level of development of
its health system. However, it is crucial to learn from other countries and regions in
terms of stories of success, errors, experiences and benefits.
For those countries which still do not have any developments in PM (i.e. Honduras,
Paraguay), it is important to first know what the situation in the country is, map
human resources and infrastructure available, and improve intra-regional
collaboration.
EULAC PerMed - D2.3 “Workshop Report” 14
Regarding the areas in which the EU-LAC cooperation in pm could be beneficial, the following were identified as the more relevant ones:
Training for researchers and for healthcare professionals
Exchange of practices and experiences of PM implementation in health systems
Collaborative research Projects
Implementation of joint research programs (i.e. ERA-PerMed).
Besides the aforementioned general areas for collaboration, LAC participants in the workshop pointed out additional and more specific issues in which collaboration could be beneficial for LAC countries:
Learn how to carry out the evaluation of PM treatments and diagnostic tools within the process of health technology assessment, sharing experiences through cooperative research.
Learn on the implementation of programs and analysis of cost-effectiveness, how to develop protocol for the evaluation of new technologies. Adequate role of HTA expertise in evaluation of research projects.
Emulating examples of funding schemes, engagement of institutions and project management.
Implementation research with a focus on scaling up interventions and PM approaches.
Find innovative ways to measure impact, in order to demonstrate PM’s long-term benefits
Create innovative operative frameworks, mechanisms for resource allocation among different working packages, and creating indicators, under a single umbrella. This is not the same as HTA, not for a single technology, but for categories of subpopulations, diseases. Endpoints are not clear.
Regarding how to facilitate and strengthen the collaboration between Europe and LAC in PM and in how the EULAC PerMed project can contribute to this goal, three main aspects were pointed out:
Research
Capacity building
Networking
Examples of possible actions in each one of these aspects are presented in Deliverable 2.2.
EULAC PerMed - D2.3 “Workshop Report” 15
Regarding which would be the best or most efficient approach to better achieve the EULAC
PerMed objective of integrating LAC countries in ICPerMed, the following approaches were
identified:
In a first step, there is a need to convince the governments.
Articulating what the rationale is and what the incentives are for each country in order
to collaborate with the EU in PM.
Health diplomacy.
International responsibility.
Finding champions for the project in the LAC region.
Build trust by very open and transparent communication on the rationale behind the
EU engagement. Transparency and communication: making it clear that there are no
economic interests underneath.
Scientific reasoning (critical mass in terms of population and most comparable to EU
population, common diseases including rare diseases), market access and volume.
…………………………………………………………………..
EULAC PerMed - D2.3 “Workshop Report” 16
ANNEX I
Agenda of the Workshop
EULAC PerMed - D2.3 “Workshop Report” 17
EULAC-PerMed: AMPLIANDO LA COOPERACIÓN POLÍTICA Y DE
INVESTIGACIÓN EN MEDICINA PERSONALIZADA ENTRE EUROPA
Y LATINO-AMÉRICA Y CARIBE
EULAC-PerMed: WIDENING EU-LAC POLICY AND RESEARCH
COOPERATION IN PERSONALISED MEDICINE
TALLER DE TRABAJO/WORKSHOP:
CONSTRUYENDO PUENTES EN MEDICINA PERSONALIZADA ENTRE AMÉRICA LATINA-CARIBE Y EUROPA/ BUILDING BRIDGES IN PERSONALISED MEDICINE BETWEEN LATIN
AMERICA-CARIBBEAN AND EUROPE
11-12 diciembre, 2019.
Parque Tecnológico LATU, Montevideo (URUGUAY)
EULAC PerMed - D2.3 “Workshop Report” 18
EULAC-PerMed
El proyecto europeo EULAC-PerMed3, tiene como objetivo final Integrar a los países de
Latinoamérica y Caribe (LAC) en el consorcio y actividades de ICPerMEd4, como un medio para
ampliar el alcance internacional de las políticas de I+D relacionadas con la Medicina
Personalizada (MP), promoviendo y favoreciendo un enfoque global para la implementación
de la MP a lo largo de toda la cadena de valor del sector salud.
El proyecto también trabajará para facilitar una medicina personalizada que beneficie a los
pacientes, los ciudadanos y la sociedad en general, con el objetivo final de contribuir al
Objetivo de Desarrollo Sostenible nº 3 de Naciones Unidas “Garantizar una vida sana y
promover el bienestar para todos en todas las edades”.
OBJETIVOS DEL TALLER
Presentar el proyecto EULAC-PerMed y los primeros resultados del estudio sobre
medicina personalizada en Latinoamérica y el Caribe (LAC) realizados en marco del
proyecto.
Analizar y debatir sobre la situación de la Medicina Personalizada en LAC, principales
barreras, retos y oportunidades.
Analizar las diferentes oportunidades de colaboración entre LAC y Europa en el campo
de la Medicina Personalizada y cómo afrontar el dialogo político y científico previsto
en el marco del proyecto EULAC-PerMed.
El taller servirá como punto de encuentro de los integrantes del proyecto EULAC-PerMed y
representantes del consorcio internacional ICPerMed con expertos europeos y latino-
americanos, representantes de Ministerios de Salud, Ministerios de Ciencia y tecnología,
agencias de financiación de la I+D, centros de investigación, industria y asociaciones de
pacientes de LAC para compartir experiencias, analizar opciones de colaboración y proponer
recomendaciones para una mejor y más fructífera colaboraciones entre las dos regiones en
este campo.
ORGANIZACIÓN
INNOVATEC – España
Agencia Nacional de Investigación e Innovación – ANII – URUGUAY
El taller ser enmarca dentro de las actividades del proyecto europeo EULAC-PerMed,
financiado por la Comisión Europea a través del Programa Marco Horizonte 2020.
El idioma del taller será el español, con traducción simultánea al inglés.
3 http://www.eulac-permed.eu/ 4 El Consorcio Internacional de Medicina Personalizad (ICPerMed) persigue abordar de manera coordinada la investigación y la implementación de la medicina personalizada. https://www.icpermed.eu
EULAC PerMed - D2.3 “Workshop Report” 19
EULAC-PerMed
The European project EULAC-PerMed 5has as final aim to integrate countries from the Latin
American and Caribbean (LAC) region into ICPerMed6 and its activities, as a means to widen
the international scope of Personalised Medicine (PM) R&I related policies, increasing and
encouraging a worldwide implementation of PM approaches across the whole healthcare
value chain. The project will also work towards facilitating the introduction of PM for the
benefit of patients, citizens and society, with the ultimate goal of contributing to the UN
Sustainable Development Goal nº 3, that is to “ensure healthy lives and promote well-being for
all at all ages”,
OBJECTIVES OF THE WORKSHOP
To present the work of the EULAC-PerMed project, mainly the results of the mapping
of Personalised Medicine in LAC.
To analyse and discuss with relevant actors from LAC the situation of Personalised
Medicine in Latin America and the Caribbean, analyzing main gaps and barriers,
opportunities and challenges ahead.
To discuss the best options to promote the collaboration between LAC and EU in
Personalised Medicine and how to best approach the science and policy dialogue to be
carried out within the EULAC-PerMed project.
The workshop brings together EULAC-PerMed partners, representatives of ICPerMed,
European and LAC experts, policy makers, funders, researchers and private business to share
knowledge, discuss options and provide recommendations towards building bridges in
personalised medicine between Latin America, the Caribbean and Europe.
ORGANIZERS
INNOVATEC – España
Agencia Nacional de Investigación e Innovación – ANII – URUGUAY
The workshop is one of the activities carried out as part of the European project EULAC-
PerMed funded by the European Commission’s Horizon 2020 Research and Innovation
programme under Grant Agreement Num. 825173.
The main language of the workshop will be Spanish, and simultaneous translation to English
will be available.
5http://www.eulac-permed.eu/ 6 The International Consortium for Personalised Medicine (ICPerMed) was initiated during several workshops organised by the European Commission throughout 2016. ICPerMed aims to provide a flexible framework for cooperation between its member organisations. https://www.icpermed.eu/
DIA 1: MIÉRCOLES 11 DICIEMBRE 2019 /DAY 1 WEDNESDAY 11TH DECEMBER 2019
EULAC PerMed - D2.3 “Workshop Report” 20
Hora/Hour
09:00-09:15 REGISTRO DE PARTICIPANTES /REGISTRATION
09:15-09:30
BIENVENIDA E INAUGURACIÓN DEL TALLER/WELCOME AND OPENING OF THE WORKSHOP
Dra. Esther Rodríguez. Coordinadora de la Oficina de proyectos europeos. Coordinadora de EULAC-PerMed. Instituto de Salud Carlos IIII, España.
Dr. Jorge Basso- Ministro de Salud Pública de Uruguay.
Ing. Fernando Brum. Presidente del Directorio de ANII Agencia Nacional de Investigación e Innovación. Uruguay.
09:.30-09:35
BREVE INTRODUCCIÓN DE LOS OBJETIVOS DEL TALLER Y LOS PARTICIPANTES /BRIEF INTRODUCTION OF THE WORKSHOP AND THE PARTICIPANTS
Joaquín Guinea/ Erika Sela INNOVATEC.
09:35-09:50 PRESENTACIÓN DEL PROYECTO EULAC-PerMed / The EULAC-PerMed PROJECT
Dra. Esther Rodriguez, ISCIII (España).
09:50-10:10
PRESENTACIÓN 1: LA PONENCIA DEL ESTUDIO SOBRE GENÓMICA DEL SENADO ESPAÑOL Y SU PAPEL PARA IMPULSAR LA ESTRATEGIA NACIONAL DE MEDICINA DE PRECISIÓN EN ESPAÑA. / KEYNOTE PRESENTATION 1: THE GENOMIC INITIATIVE OF THE SPANISH SENATE AND ITS ROLE IN PROMOTING THE NATIONAL STRATEGY OF PRECISION MEDICINE IN SPAIN. Dr. José Martínez Olmos. Escuela Andaluza de Salud Pública. Ex-senador y ex Portavoz de la Comisión de Sanidad y Servicios Sociales.
10:10 –10:30
PRESENTACIÓN 2: UNA VISIÓN DE LA MEDICINA PERSONALIZADA DESDE AMÉRICA LATINA / KEYNOTE PRESENTATION 2: A VISION OF PERSONALISED MEDICINE FROM LATIN AMERICA AND CARIBBEAN. Dr. Manoel Barral-Netto. FIOCRUZ (Brasil)
10:30-11:00 CAFÉ /COFEE BREAK
LA SITUACIÓN DE LA MEDICINA PERSONALIZADA EN AMERICA LATINA Y EL CARIBE THE SITUATION OF PERSONALISED MEDICINE IN LATIN AMERICA AND THE CARIBBEAN.
11:00-11:20
PRESENTACIÓN DE LOS RESULTADOS DEL ESTUDIO SOBRE MEDICINA PERSONALIZADA EN PAÍSES DE AMÉRICA LATINA Y EL CARIBE/ PRESENTATION OF THE RESULTS OF THE STUDY “MAPPING OF PERSONALISED MEDICINE IN LAC COUNTRIES”. Joaquín Guinea/ Erika Sela, INNOVATEC (España) Dr. Franz F. Castro, Instituto GORGAS (Panamá).
EULAC PerMed - D2.3 “Workshop Report” 21
11.20-13:00
MESA REDONDA. APRENDIENDO DE DIFERENTES INICIATIVAS DE MP EN PAÍSES DE AMÉRICA LATINA / LEARNING ABOUT PM INITIATIVES IN LATIN AMERICA.
Moderador: Erika Sela, INNOVATEC
MEXICO: "La investigación en los Institutos Nacionales de Salud hacia la Medicina Personalizada" Dr. Rodolfo Cano Jiménez. Director de Investigación en Salud. Secretaria de Salud.
BRAZIL: “La Iniciativa brasileña de Medicina de Precisión BIPMed”. Dra. Iscia Lopes Cendes. Universidade Estadual de Campinas (UNICAMP). Faculdade de Ciências Médicas (FCM).
CUBA: “El Programa Nacional de Medicina de Precisión”. Dra. María Victoria Norabuena Canal, Jefa del Departamento de Investigaciones de la Dirección de Ciencia Tecnología e Innovación. Ministerio de Salud Pública
CHILE: "Implementación de la oncología de precisión: de la investigación a la práctica clínica". Dr. Ricardo Armisén, Director Científico. Centro de Excelencia en Medicina de Precisión (CEMP).
PERÚ: “Experiencia de estudios de Medicina de Precisión: Universidad San Martin de Porres” Dra. Liliana Vásquez, Investigador principal, Centro de Medicina de Precisión de la Facultad de Medicina - Universidad de San Martin de Porres.
COLOMBIA: Cerrando brechas de la medicina de precisión en Colombia: GenomaCES Biotechnologies. Dr. Juan Esteban Gallo, fundador y director científico.
ARGENTINA: “Iniciativas argentinas en medicina de precisión”. Licc. Azul Irazoqui y Licc Agustina Vello. Secretaría de Ciencia, Tecnología e Innovación Productiva de la Nación, Gobierno de Argentina.
URUGUAY. Oportunidades para el desarrollo de la medicina predictiva en oncologia. Investigación y práctica clínica. Dr. Mauricio Cuello. Profesor asociado del Servicio de oncología, Hospital Manuel Quintela. Subdirector del Instituto Nacional del Cáncer de Uruguay.
13:00-13:30 PREGUNTAS Y DEBATE / QUESTIONS AND DISCUSSION
13:30-14:30 ALMUERZO /LUNCH
RETOS Y PERSPECTIVAS DE FUTURO PARA LA MEDICINA PERSONALIZAD EN AMÉRICA LATINA Y EL CARIBE. CHALLENGES AND FUTURE PERSPECTIVES OF PERSONALISED MEDICINE IN LATIN AMERICA AND THE
CARIBBEAN Moderador: Joaquín Guinea (INNOVATEC)
14:30-14:45
LAS POLÍTICAS DE INNOVACIÓN EN SALUD EN AMÉRICA LATINA Y SU PAPEL EN EL DESARROLLO
DE LA MEDICINA PERSONALIZADA. RESULTADOS DEL ESTUDIO DE RIMAIS/ HEALTH
INNOVATION POLICIES IN LATIN AMERICA AND ITS ROLE AS DRIVERS OF PERSONALISED
MEDICINE. PRESENTATION FROM THE RIMAIS STUDY
Dr. Tomás López-Peña. ISCIII (España)/RIMAIS
14:45-15:00
RESULTADOS DE LA ENCUESTA SOBRE RETOS Y FUTURO DE LA MP EN LAC/RESULTS OF THE
SURVEY CHALLENGES AND PERSPECTIVES OF PERSONALISED MEDICINE IN LATIN AMERICA AND
THE CARIBBEAN
Dr. Juan Miguel Pascale/Dr. Franz F. Castro, Instituto GORGAS (Panamá).
15:00-16:30 RETOS Y FUTURO DE LA MP EN LAC. SESIONES DE TRABAJO PARALELAS EN 4 GRUPOS DE
TRABAJO/ CHALLENGES AND FUTURE OF PM IN LAC. DISCUSSION IN 4 WORKING GROUPS
EULAC PerMed - D2.3 “Workshop Report” 22
GRUPO 1:
Moderador: Paula
García (ECRIN)
Rapporteur: María
Gamboa (ISCIII)
GRUPO 2:
Moderador: Juan
Miguel Pascale
(GORGAS)
Rapporteur Erika Sela
(INNOVATEC)
GRUPO 3:
Moderador: Joaquín
Guinea (INNOVATEC)
Rapporteur Manoel
Barral (FIOCRUZ)
GRUPO 4:
Moderador: Ulrike
Busholff (DLR)
Rapporteur: Franz
Castro (GORGAS)
(English speaking)
16:30-17-00 CAFÉ /COFEE
17:00-17:30
SESIÓN PLENARIA: PRESENTACIÓN DE LOS RESULTADOS DE LOS DIFERENTES GRUPOS.
/PLENARY SESSION: PRESENTATION OF THE RESULTS OF THE GROUP DISCUSSION AND
SUMMARY OF MAIN FINDINGS.
Moderador: Dr. Juan Miguel Pascale/ Dr. Franz F. Castro, Instituto GORGAS (Panamá).
17:30 CLAUSURA DEL DÍA /CLOSING OF THE DAY
19:30 - 22:00 EVENTO SOCIAL /SOCIAL EVENT CENA -DINNER
EULAC PerMed - D2.3 “Workshop Report” 23
DIA 2: JUEVES, 12 DICIEMBRE 2019 / DAY 2: THURSDAY, 12TH DECEMBER 2019
HORA/HOUR
09:00-9:10 APERTURA DEL TALLER E INTRODUCCIÓN DE LA AGENDA DEL DÍA/ OPENING OF THE WORKSHOP AND INTRODUCTION OF THE DAY AGENDA
PRESENTACIONES INVITADAS /INVITED PRESENTATIONS
09:10- 10:45
THE ICPerMed INTERNATIONAL CONSORTIUM FOR PERSONALISED MEDICINE. Dra. Ulrike Busshoff, ICPerMed secretariat, DLR (Germany).
CNPq ACTIVITIES IN PERSONALISED MEDICINE. Professor João Azevedo, President of CNPq, National Council for Scientific and Technological Development (Brazil)
CELAC AND EUROPEAN CONSORTIUM FOR A PERSONALISED MEDICINE APPROACH TO GASTRIC CANCER (LEGACy). Dra. Tania Fleitas Kanonnikoff- INCLIVA (España). Coordinadora del Proyecto.
PERSPECTIVAS Y DESAFÍOS DE LOS BIOBANCOS DE MATERIAL BIOLÓGICO HUMANO EN EL AVANCE DE LA MEDICINA PERSONALIZADA: EXPERIENCIA DE LA RED DE BIOBANCOS DE LATINOAMÉRICA Y DEL CARIBE (REBLAC). Dr. Gustavo Stefanoff. Coordinador de la Red de Biobancos de Latinoamérica y del Caribe (REBLAC). Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA), (Brasil)
ERA-PerMED, ERA-NET ON PERSONALISED MEDICINE Dra. Esther Rodriguez, ISCIII (España)
10:45-11:15 CAFÉ /COFEE
FORTALECIENDO LA COLABORACIÓN ENTRE EUROPA Y AMERICA-LATINA Y CARIBE EN MEDICINA PERSONALIZADA / STRENGTHENING THE EU-LAC COLABORATION IN PERSONALISED MEDICINE
Moderadores: María José Ruíz Álvarez (Ministerio Salud, Italia) /Manoel Barral (FIOCRUZ, Brasil)
11:15-11:35 SCIENCE & POLICY DIALOGUE BETWEEN LAC COUNTRIES AND ICPERMED. NEXT STEPS.
Laura de la Cruz - DLR (Alemania)
11:35-13:00
COMO FORTALECER LA COLABORACIÓN EU-LAC EN MEDICINA PERSONALIZADA/ HOW TO STRENGTHEN THE COLLABORATION BETWEEN LAC AND EU COUNTRIES IN PERSONALISED MEDICINE) Introducción a las sesiones en grupo / Introduction to the working group session. Joaquín Guinea INNOVATEC /Franz Castro (Instituto GORGAS)
GRUPO 1:
Moderador: Paula
García (ECRIN)
Rapporteur: María Gamboa (ISCIII)
GRUPO 2:
Moderador: Juan
Miguel Pascale
(GORGAS)
Rapporteur Erika Sela
(INNOVATEC)
GRUPO 3:
Moderador: Joaquín
Guinea (INNOVATEC)
Rapporteur Manoel Barral (FIOCRUZ)
GRUPO 4:
Moderador: Ulrike
Busshoff, (DLR)
Rapporteur: Franz Castro (GORGAS) (English Speaking)
13:00-13:30
PRESENTACIÓN DE LOS RESULTADOS DE LOS GRUPOS Y PRINCIPALES RECOMENDACIONES PARA FORTALECER LA COLABORACIÓN EU-LAC EN MP / PRESENTATIONS OF RESULTS FROM THE DISCUSSION GROUPS TO THE AUDIENCE BY THE RAPPORTEURS Moderadores: María José Ruíz Álvarez (Ministerio Salud, Italia) /Manoel Barral (FIOCRUZ, Brasil)
13:30
CONCLUSIONES Y CLAUSURA DEL TALLER / WRAP UP AND CLOSING
Joaquin Guinea (Innovatec, España)
Esther Rodriguez (ISCIII, España)
13:30-14:30 ALMUERZO /LUNCH